RDSC — what changed in the latest 10-Q
A section-by-section comparison of RDSC's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-25 vs the prior 10-Q · 2026-02-26
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +6 | −14 | ~18 | 45 |
| Market risk (Item 3) | Text added/removed | +6 | −14 | ~18 | 44 |
| Controls & procedures | Text added/removed | +6 | −14 | ~18 | 44 |
| Legal proceedings | Text added/removed | +6 | −14 | ~18 | 44 |
| Other information | Text added/removed | +6 | −14 | ~18 | 43 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-25
Weighted average number of common shares outstanding, basic and diluted 25,912,500 22,000,000
The accompanying notes are an integral part of these consolidated financial statements.
Effect of exchange rate changes on cash and cash equivalent $697 $265
Cash and cash equivalents, beginning of period 13,740 17,623
The accompanying notes are an integral part of these consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-02-26
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
COMMON STOCK ADDITIONAL PAID-IN CAPITAL ACCUMULATED OTHER COMPREHENSIVE (LOSS) / GAIN ACCUMULATED (DEFICIT) / PROFIT TOTAL EQUITY
The accompanying notes are an integral part of these audited consolidated financial statements.
FOR THE NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-25
Weighted average number of common shares outstanding, basic and diluted 25,912,500 22,000,000
The accompanying notes are an integral part of these consolidated financial statements.
Effect of exchange rate changes on cash and cash equivalent $697 $265
Cash and cash equivalents, beginning of period 13,740 17,623
The accompanying notes are an integral part of these consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-02-26
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
COMMON STOCK ADDITIONAL PAID-IN CAPITAL ACCUMULATED OTHER COMPREHENSIVE (LOSS) / GAIN ACCUMULATED (DEFICIT) / PROFIT TOTAL EQUITY
The accompanying notes are an integral part of these audited consolidated financial statements.
FOR THE NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-25
Weighted average number of common shares outstanding, basic and diluted 25,912,500 22,000,000
The accompanying notes are an integral part of these consolidated financial statements.
Effect of exchange rate changes on cash and cash equivalent $697 $265
Cash and cash equivalents, beginning of period 13,740 17,623
The accompanying notes are an integral part of these consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-02-26
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
COMMON STOCK ADDITIONAL PAID-IN CAPITAL ACCUMULATED OTHER COMPREHENSIVE (LOSS) / GAIN ACCUMULATED (DEFICIT) / PROFIT TOTAL EQUITY
The accompanying notes are an integral part of these audited consolidated financial statements.
FOR THE NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-25
Weighted average number of common shares outstanding, basic and diluted 25,912,500 22,000,000
The accompanying notes are an integral part of these consolidated financial statements.
Effect of exchange rate changes on cash and cash equivalent $697 $265
Cash and cash equivalents, beginning of period 13,740 17,623
The accompanying notes are an integral part of these consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-02-26
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
COMMON STOCK ADDITIONAL PAID-IN CAPITAL ACCUMULATED OTHER COMPREHENSIVE (LOSS) / GAIN ACCUMULATED (DEFICIT) / PROFIT TOTAL EQUITY
The accompanying notes are an integral part of these audited consolidated financial statements.
FOR THE NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-25
Weighted average number of common shares outstanding, basic and diluted 25,912,500 22,000,000
The accompanying notes are an integral part of these consolidated financial statements.
Effect of exchange rate changes on cash and cash equivalent $697 $265
Cash and cash equivalents, beginning of period 13,740 17,623
The accompanying notes are an integral part of these consolidated financial statements.
Text removed vs the prior filing · source: 10-Q · 2026-02-26
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
COMMON STOCK ADDITIONAL PAID-IN CAPITAL ACCUMULATED OTHER COMPREHENSIVE (LOSS) / GAIN ACCUMULATED (DEFICIT) / PROFIT TOTAL EQUITY
The accompanying notes are an integral part of these audited consolidated financial statements.
FOR THE NINE MONTHS ENDED JANUARY 31, 2026 AND FROM JANUARY 20, 2025 (DATE OF INCEPTION) TO APRIL 30, 2025
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice